CEO of GSK plays down its role in FDA effort to approve therapy for autism-related condition

Taking stock of the drug industry, from the lab to the medicine chest

October 15, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Jeff Pinette for STAT STAT+ | CEO of GSK plays down its role in FDA effort to approve therapy for autism-related condition The drugmaker has no commercial or scientific interest in the FDA matter, Emma Walmsley says at the STAT Summit in Boston. By Elaine Chen STAT+ | German biotech Tubulis raises $358 million to advance cancer treatments The company, which is developing antibody-drug conjugates, will use the funding to push its lead drug candidate into trials in additional types of cancer.  By Andrew Joseph Doctor groups need to 'step up to the plate' as CDC guidance becomes harder to trust, former leaders say Layoffs, leadership changes, and underlying political agendas have made CDC information less trustworthy, former CDC officials say at STAT Summit Boston. By Chelsea Cirruzzo

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser